Resistant cells were sensitised to the CDK4/CDK6 inhibitor palbociclib, which is currently approved for therapy of certain breast cancers and, like other CDK4/CDK6 inhibitors, is undergoing clinical trials for other types of cancer42. Here, CDK4 is linked to breast carcinoma.